DHTRF (DRI Healthcare Trust) ROCE %: % (As of Mar. 2026)


DHTRF DRI Healthcare Trust DHTRF
33 GF Score
Price $12.70
GF Value $13.28
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is DRI Healthcare Trust ROCE %?

DRI Healthcare Trust DHTRF 33 ROCE % is % as of Mar. 2026. GuruFocus rates DHTRF with a GF Score™ of 33/100 and a GF Value™ of $13.28 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % does not apply to banks and insurance companies.

DHTRF
33GF Score
DRI Healthcare Trust DHTRF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of % mean?
DRI Healthcare Trust (DHTRF) has a ROCE % of % as of Mar. 2026.
Is DRI Healthcare Trust's ROCE % too high?
DRI Healthcare Trust's current ROCE % is %. Overall, DRI Healthcare Trust has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DRI Healthcare Trust's ROCE % compare to ZTS and UTHR?
DRI Healthcare Trust's ROCE % of % can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DRI Healthcare Trust's current ROCE % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DRI Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, DRI Healthcare Trust (DHTRF) is currently considered Fairly Valued. The stock's GF Value™ is $13.28, compared to a current price of $12.70 — trading 4.4% below its estimated fair value. The current ROCE % is %. DRI Healthcare Trust's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For DRI Healthcare Trust (DHTRF), the current ROCE % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?

Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be undervalued. The current stock price of $12.70 is trading 4.4% below its estimated GF Value™ of $13.28. GuruFocus considers DRI Healthcare Trust to be Fairly Valued.

Key valuation signals for DHTRF:

  • ROCE %: %
  • GF Value™: $13.28 vs. price of $12.70 (4.4% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DRI Healthcare Trust Business Description

Other Exchanges DHT.UN:CanadaDHT.U:Canada
Address 100 King Street West, 1 First Canadian Place, Suite 6200, Toronto, ON, CAN, M5X 1B8
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
33GF Score

Get the complete analysis for DHTRF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.70
Price
$13.28
GF Value